Your browser doesn't support javascript.
loading
Cardiotoxicity in autologous haematopoietic stem cell transplantation for systemic sclerosis.
Penglase, Ross; Girgis, Laila; Englert, Helen; Brennan, Xavier; Jabbour, Andrew; Kotlyar, Eugene; Ma, David; Moore, John.
Afiliação
  • Penglase R; Department of Rheumatology, St. Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.
  • Girgis L; University of New South Wales, Sydney, NSW, Australia.
  • Englert H; St. Vincent's Centre for Applied Medical Research, Darlinghurst, NSW, Australia.
  • Brennan X; Department of Rheumatology, St. Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.
  • Jabbour A; University of New South Wales, Sydney, NSW, Australia.
  • Kotlyar E; St. Vincent's Centre for Applied Medical Research, Darlinghurst, NSW, Australia.
  • Ma D; Department of Haematology and BM Transplantation, St. Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.
  • Moore J; Department of Cardiology and Heart and Lung Transplantation, St. Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.
J Scleroderma Relat Disord ; 8(2): 87-100, 2023 Jun.
Article em En | MEDLINE | ID: mdl-37287946
Autologous haematopoietic stem cell transplantation is now well-established as an effective treatment for severe systemic sclerosis with clear demonstration of favourable end-organ and survival outcomes. Treatment-related cardiotoxicity remains the predominant safety concern and contraindicates autologous haematopoietic stem cell transplantation in patients with severe cardiopulmonary disease. In this review, we describe the cardiovascular outcomes of autologous haematopoietic stem cell transplantation recipients, discuss the potential mechanisms of cardiotoxicity and propose future mitigating strategies.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article